Related Experiment Video

Updated: Jun 6, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

The epidermal growth factor receptor family in breast cancer

Angelos K Koutras1, T R Jeffry Evans

  • 1Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom.

Oncotargets and Therapy
|December 4, 2010
PubMed

Insights

The Human Epidermal Growth Factor Receptor (HER) family, including HER-2, HER-3, and HER-4, plays a crucial role in breast cancer. Understanding their signaling pathways and expression patterns is vital for prognosis and targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The Human Epidermal Growth Factor Receptor (HER) family, comprising EGFR, HER-2, HER-3, and HER-4, is implicated in various human malignancies.
  • Deregulation of HER signaling pathways is a hallmark of several cancers, with HER-2 recognized as a key oncogene in breast cancer.
  • HER-2 status is critical for breast cancer prognosis and predicting response to therapies like trastuzumab.

Purpose of the Study:

  • To review the current evidence on the role of the entire HER family as a panel in breast cancer.
  • To provide an update on the significance of HER-3 and HER-4 alterations in breast carcinogenesis.
  • To highlight novel methods for determining HER family status and review therapeutic strategies targeting the HER family.

Main Methods:

  • Literature review of current evidence on HER family signaling in breast cancer.
  • Analysis of data regarding the prognostic value of HER family members.
  • Discussion of novel diagnostic methods like real-time polymerase chain reaction.
  • Review of therapeutic approaches targeting the HER family.

Main Results:

  • HER-2 is a key oncogene in breast cancer, crucial for prognosis and predicting treatment response.
  • Alterations in HER-3 and HER-4 also contribute significantly to breast carcinogenesis.
  • Combined evaluation of all HER family members' expression patterns is of significant interest due to complex receptor interactions.
  • Novel methods like real-time PCR offer advanced ways to determine HER family status.

Conclusions:

  • The HER family, as a collective panel, plays a pivotal role in breast cancer pathogenesis and progression.
  • Accurate assessment of HER family members, particularly HER-2, HER-3, and HER-4, is essential for patient prognosis and personalized treatment strategies.
  • Targeting the HER family pathways represents a promising therapeutic avenue for breast cancer patients.
Keywords:
breast cancerepidermal growth factorreceptor

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...